Börskollen
Pressmeddelanden från Circio
Idag 14:45
CircioCircio selected for oral presentation at prestigious ASGCT annual meeting26 feb 07:00CircioCircio presents groundbreaking in vivo data showing up to 50-fold enhanced circVec-AAV gene expression in eye19 feb 07:00CircioCircio invites to R&D and corporate update webcast on 26 February 202617 feb 10:33CircioCircio Holding ASA: Registration of share capital increase following directed issue of NOK 3.6 million16 feb 07:00CircioCIRCIO HOLDING ASA: INFORMATION ABOUT WARRANTS AND COMMENCEMENT OF TRADING14 feb 09:57CircioCircio announces allocation of stock options to key employees12 feb 12:19CircioCircio Holding ASA: Registration of share capital increase following rights issue and private placement06 feb 11:48CircioCircio Holding ASA completes directed issue of NOK 3.6 million30 jan 19:44CircioCircio Holding ASA – Mandatory notification of trade by primary insiders and close associates related to the rights issue and private placement30 jan 14:11CircioCircio Holding ASA – Final results of the oversubscribed rights issue29 jan 21:43CircioCircio Holding ASA announces substantially oversubscribed preliminary result of the rights issue29 jan 09:32CircioCircio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders29 jan 07:00CircioCircio Holding ASA – Subscription period for the rights issue expires today28 jan 13:37CircioCircio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders23 jan 07:00CircioCircio Holding ASA – Last day of trading in subscription rights in the rights issue22 jan 10:50CircioAnalyst Group publishes initiation report on Circio21 jan 15:12CircioCircio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders16 jan 14:06CircioCircio Holding ASA – Exercise of subscription rights in the rights issue by primary insiders15 jan 15:12CircioCircio Holding ASA – Receipt of subscription rights in the rights issue by primary insiders and their close associates15 jan 07:00CircioCircio Holding ASA – Commencement of the subscription period for the rights issue13 jan 12:23CircioCircio Holding ASA – Approval and publication of prospectus for the rights issue13 jan 07:00CircioCircio Holding ASA – Ex. subscription rights today12 jan 22:19CircioCircio Holding ASA – Minutes from the extraordinary general meeting 2026 and approval of Rights Issue12 jan 15:30CircioCircio invites to live webcast on 15 January 2026 to provide information about the upcoming rights issue12 jan 15:15CircioCircio Holding ASA – Extraordinary general meeting held, all agenda items approved09 jan 07:00CircioCircio Holding ASA – Updated key information relating to the rights issue07 jan 17:00CircioCircio and The University of Texas Medical Branch jointly announce collaboration to evaluate circVec for the treatment of infectious diseases23 dec 2025 09:11CircioCorrection: Circio Holding ASA – Updated information to the notice of extraordinary general meeting 202623 dec 2025 09:02CircioCircio Holding ASA – Updated information to the notice of extraordinary general meeting 202519 dec 2025 14:24CircioCircio Holding ASA – Notice of extraordinary general meeting on 12 January 202608 dec 2025 10:00CircioCircio Holding ASA – Key information related to the rights issue08 dec 2025 07:00CircioCircio announces 88% underwritten and presubscribed NOK 50 million rights issue with strong support from existing shareholders24 nov 2025 07:00CircioCircio presents data that further strengthens and broadens its circVec circular RNA expression platform17 nov 2025 14:00CircioCircio issues invitation to R&D and corporate update webcast on 24 November 202519 okt 2025 21:45CircioCircio Holding ASA – Bond conversion and additional trading restrictions17 okt 2025 16:39CircioCircio Holding ASA: Requested Conversion of Convertible Bonds15 okt 2025 11:14CircioCircio Holding ASA: Requested Conversion of Convertible Bonds08 okt 2025 07:00CircioCircio presents comprehensive circVec in vivo data package demonstrating 40-fold improvement over conventional AAV gene delivery at ESGCT 202506 okt 2025 12:07CircioCircio Holding ASA: Requested Conversion of Convertible Bonds01 okt 2025 16:55CircioCircio Holding ASA – Approval and publication of prospectus for potential future share issues and conversion of convertible bonds01 okt 2025 07:00CircioCircio to present comprehensive circVec-AAV in vivo data package at ESGCT 202509 sep 2025 09:53CircioCircio Holding ASA: Registration of share capital increase following conversion of convertible bonds05 sep 2025 10:29CircioCircio Holding ASA - Conversion of Convertible Bonds and funding requested under Additional Financing Commitment from Atlas28 aug 2025 07:00CircioCircio presents new circVec-AAV vectors showing up to 40x enhanced activity in first half year report webcast21 aug 2025 07:00CircioCircio invites to first half 2025 report and R&D update webcast on 28 August04 aug 2025 10:57CircioCircio Holding ASA – Funding requested under additional financing commitment from Atlas07 jul 2025 07:00CircioCircio expanding its R&D operations in Stockholm to accelerate circVec development30 jun 2025 07:00CircioNeoRegen Biotech and Circio advance circular RNA delivery collaboration into in vivo stage16 jun 2025 07:00CircioTG01 mutant RAS cancer vaccine data showing clinical benefit in multiple myeloma presented at EHA 202528 maj 2025 07:00CircioCircio presents new and differentiating circVec data and corporate update in live webcast22 maj 2025 07:00CircioCircio invites to R&D and corporate update webcast on 28 May 202514 maj 2025 01:00CircioCircular RNA innovator Circio presents strengthened circVec gene therapy data at ASGCT 202506 maj 2025 07:00CircioCircular RNA innovator Circio to present strengthened circVec gene therapy data at ASGCT 202511 apr 2025 20:00CircioCircio Holding ASA: Annual Report 2024 - Correction to ESEF-file name11 apr 2025 18:54CircioCircio Holding ASA: Annual Report 202410 apr 2025 23:25CircioCircio Holding ASA: Annual Report 202403 apr 2025 07:00CircioEntos Pharmaceuticals and Circio initiate collaboration to test novel platform for circVec circular RNA delivery26 mar 2025 08:40CircioCircio presents R&D and corporate update in live webcast19 mar 2025 10:00CircioCircio invites to corporate update webcast on 26 March 202505 mar 2025 11:00CircioCircio presents results that further validate the circVec circular RNA platform at two international industry conferences03 mar 2025 07:00CircioCircio´s leading position in circular RNA therapeutics highlighted by continued broad coverage in international life science industry media26 feb 2025 07:00CircioCircio invited to present advantages of circVec circular RNA technology at international industry conferences21 jan 2025 07:00Circio4basebio partners with Circio to build and test circVec synthetic DNA vectors for genetic medicine and vaccines13 jan 2025 08:00CircioCircio publishes wide-ranging review on potential of circular RNA therapeutics in Nature Reviews Genetics06 jan 2025 10:39CircioCircio Holding ASA: Registration of share capital increase following warrant exercise and private placement19 dec 2024 08:45CircioCircio Holding ASA - Final results of the warrant exercise18 dec 2024 18:36CircioCircio raises NOK 10.7 million in upsized offering from new and existing shareholders18 dec 2024 18:16CircioCircio Holding ASA - Preliminary results of the warrant exercise18 dec 2024 12:49CircioCircio Holding ASA - Allocation of Available Warrants and Private Placement completed18 dec 2024 08:00CircioCircio Holding ASA – Last day of exercise period for warrants issued in July 202417 dec 2024 13:21CircioCircio Holding ASA – Transfer of rights to warrants from primary insiders17 dec 2024 11:27CircioCircio Holding ASA – Application for additional warrants for the subscription of new shares by primary insider17 dec 2024 10:20CircioCircio Holding ASA – Application for additional warrants for the subscription of new shares by primary insider CEO Erik D Wiklund17 dec 2024 08:00CircioCircio Holding ASA – Exercise of Warrants by primary insiders on the Board of Directors15 dec 2024 11:26CircioCircio Holding ASA – Invitation to receive Warrants and subscribe for new shares13 dec 2024 08:00CircioCircio Holding ASA – Exercise of Warrants by primary insider11 dec 2024 08:00CircioCircio Holding ASA – Exercise of Warrants by primary insider10 dec 2024 08:00CircioCircio Holding ASA – Exercise of Warrants by primary insider09 dec 2024 08:00CircioCircio Holding ASA – Exercise of Warrants by primary insider05 dec 2024 10:50CircioCircio Holding ASA – Exercise of Warrants by primary insider CEO Erik D Wiklund04 dec 2024 08:00CircioCircio announces novel circVec 3.0 generation and circular mRNA half-life up to 75 times longer than linear mRNA in vivo04 dec 2024 07:00CircioCircio Holding ASA - Commencement of exercise period for warrants issued in July 202419 nov 2024 12:00CircioCircio announces circVec LNP-delivery collaboration with Certest progressing to in vivo testing24 okt 2024 12:00CircioCircio presents circVec circular RNA in vivo expression proof-of-concept data at ESGCT 2024 annual meeting24 sep 2024 07:00CircioCircio selected for oral presentation at ESGCT 2024 annual meeting26 aug 2024 11:57CircioCircio Holding ASA: Invitation to first half-year 2024 presentation on Thursday 29 August at 10:00am CEST26 jun 2024 10:35CircioCircio Holding ASA – Link to online subscription in the rights issue26 jun 2024 07:00CircioCircio invited to present circVec circular RNA technology at upcoming international RNA therapeutics conferences25 jun 2024 07:00CircioCircio´s leading position in circular RNA therapeutics highlighted by broad recent coverage in international life science industry media17 jun 2024 11:34CircioCircio announces strengthened in vivo data and enhanced circVec 2.2 design, presented by management in R&D webcast29 maj 2024 07:00CircioCircio Holding ASA - Terms of the rights issue and related transactions29 maj 2024 07:00CircioCircio announces financing that secures cash runway for twelve months25 apr 2024 23:49CircioCircio Holding ASA: Annual Report 202317 apr 2024 08:00CircioCircio announces in vivo proof-of-concept for its circVec circular RNA platform technology and reinforced gene therapy focus17 apr 2024 07:55CircioCircio announces intention to raise around NOK 50-60 million in Q2 2024 to extend cash runway to Q2 202517 apr 2024 07:50CircioCircio terminates TG01 cancer vaccine license option agreement with IOVaxis in China for non-payment19 mar 2024 12:43CircioCircio announces that partner IOVaxis Therapeutics has exercised the option for an exclusive license to mutant RAS cancer vaccine TG01 in China04 mar 2024 16:31CircioThe TG01 IND application by Circio’s partner IOVaxis Therapeutics has been approved by the Chinese regulatory authorities27 feb 2024 07:00CircioCircio to participate in the Annual European Life Sciences CEO Forum in Zürich01 feb 2024 07:00CircioThe first patient has been dosed in Circio's TG01 triple combination study
CircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircioCircio